NEW YORK (GenomeWeb) – Biodesix today announced that UnitedHealthcare has issued a positive coverage decision for the VeriStrat test for advanced non-small cell lung cancer. 

UnitedHealthcare covers 44.7 million lives in the US. 

VeriStrat is a blood-based proteomic test that provides prognostic and predictive data to help guide treatment of patients with advanced NSCLC. Those with VeriStrat Poor test results have a shorter medical overall survival that those with VeriStrat Good results, Boulder, Colorado-based Biodesix said. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.